Palonosetron (hydrochloride)

Palonosetron (hydrochloride)

• CAS Number: 135729-62-3
• UNSPSC Description: Palonosetron hydrochloride is a 5-HT3 antagonist primarily used to prevent acute, delayed, and overall chemotherapy-induced nausea and vomiting. In addition, Palonosetron hydrochloride exhibits moderate anti-flavivirus activity and potent anti-Zika virus activity in mammalian cells. Palonosetron hydrochloride also possesses antidepressant activity[1][2][3][4].
• Target Antigen: 5-HT Receptor; Flavivirus
• Type: Reference compound
• Related Pathways: Anti-infection;GPCR/G Protein;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Palonosetron-Hydrochloride.html
• Purity: 99.96
• Solubility: DMSO : 3.33 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
• Smiles: O=C1N(C[C@@]([H])(CCC2)C3=C2C=CC=C13)[C@@H]4CN5CCC4CC5.[H]Cl
• Molecular Weight: 332.87
• References & Citations: [1]Barrows, et al. "A screen of FDA-approved drugs for inhibitors of Zika virus infection." Cell host & microbe 20.2 (2016): 259-270.|[2]Rojas, et al. "Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor." Anesthesia & Analgesia 107.2 (2008): 469-478.|[3]Wallenborn, et al. "Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting." Clinical Medicine Insights: Therapeutics 2 (2010): CMT-S4016.|[4]Sepúlveda-Vildósola, et al. "Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children." Archives of medical research 39.6 (2008): 601-606.|[5]Sharma J, et al. Evaluation of antidepressant effect of palonosetron in Swiss albino mice[J]. National Journal of Pharmacology and Therapeutics, 2023, 1(2): 98-100.|[6]Rojas C, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010 Nov;335(2):362-8.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched